Posts for Ticker ‘DCGN’

More ‘Going Concern’ Notes Hitting Companies (AWBC, AHR, BWTR, CHCI, DCGN, GST, MLP, OXGN, TMI, XCR)

burning-money-picThis might be a record year for auditor “going concern” notes being included in annual report filings with the SEC. If it isn’t a record, it sure feels like it.  This note in an annual report is either from the company or its auditor(s) that there is a risk that the company will not be able to operate without bringing in new capital or be operated in the same manner financially.
Read More »

Posted on: April 1, 2009 – 10:07 am in Accounting, Annual Report, SEC, , , , , , , , , ,

Can deCODE Genetics Escape Icelandic Woes? (DCGN)

Decode_logo_2If you think things are bad here in the U.S., Iceland is experiencing something far worse.  The country is on the verge of teetering, it is nationalizing its banks, and it is on the verge of hyper inflation.  It is nearly impossible for U.S. investors to invest in anything liquid in the country via closed end funds or by ADR shares.  But there is one stock: deCODE genetics Inc. (NASDAQ: DCGN).

Read More »

Posted on: October 9, 2008 – 7:54 am in ADR, Biotech,

Top 10 Pre-Market Analyst Calls (ADBE, BIIB, DAI, DCGN, EBAY, HOG, JPM, WFC, MFE, MPEL, TIBX)

These are not at all the only key impact analyst calls, but these are the early bird calls that 247WallSt.com is focusing on:

  • Adobe (NASDAQ: ADBE) downgraded to Neutral from Buy at UBS.
  • Biogen Idec (NASDAQ: BIIB) raised to Buy from Neutral at Banc of America.
  • Daimler (NYSE: DAI) downgraded to Market Perform at Bernstein.
  • deCODE Genetics (NASDAQ: DCGN) downgraded to Underweight at Lehman.
  • eBay (NASDAQ: EBAY) raised to Outperform from Peer Perform at Bear Stearns.
  • Harley Davidson (NYSE: HOG) downgraded to SELL from Hold at Citigroup.
  • JPMorgan Chase (NYSE: JPM) & Wells Fargo (NYSE: WFC) were both downgraded to Peer Perform at Oppenheimer.
  • McAfee (NYSE: MFE) downgraded to Neutral from Buy at UBS.
  • Melco PBL Entertainment (NASDAQ: MPEL) raised to Buy from Neutral at UBS.
  • TIBCO Software (NASDAQ: TIBX) raised to Buy from Hold at Citigroup.

Jon C. Ogg
January 17, 2008

Posted on: January 17, 2008 – 7:09 am in Analyst Calls, , , , , , , , , , ,

Pre-Market Stock News (June 25, 2007)

(AAPL) Apple’s iTunes passed Amazon.com in music sales to become #3 music seller behind Best Buy and Wal-Mart.
(AFOP) Alliance Fiber Optics raised Q2 sales guidance.
(AGN) Allergan trades ex-split to reflect a 2-1 stock split today.
(BNT) Bentley Pharmaceuticals reported positive results with Nasulin intranasal insulin spray at the American Diabetes Association sessions.
(BX) Blackstone was the cover story for Barron’s, noted somewhat cautiously.
(DCGN) deCODE genetics announces positive clinical results for DG041 lead product candidate.
(EBAY) eBay has reportedly sent back some of the ad business to Google that it recently pulled.
(ESRX) Express Scripts trades ex-split today to reflect a 2-1 stock split.
(FRH) Freedom Acquisition Holdings is becoming a public hedge fund and alternative investment vehicle as GLG Partners a $3.4 Billion total compensation deal.
(GILD) Gilead trades ex-split today to reflect a 2-1 stock split.
(GIVN) Given Imaging could revolutionize colonoscopies according to Cramer.
(GPCB) GPC Biotech announced a partnership for Satraplatin in Japan with Yakult Honsha Co. Ltd. And will receive close to a $10 million payment plus royalties.
(HNSN) Hansen Medical has initiated legal action against Luna Innovations over trade secrets, unfair competition and breach of contract on fiber optic technologies for use in robotic catheter products and related intellectual property.
(KVHI) KVH Industries received a $1.1 million fiber optic gyro order for military simulators.
(LRY) Liberty Property established a $50 million buyback program as part of a total $100 million buyback plan.
(MRK) Merck announced that JANUVIA in combination with metaformin provided significant glycemic improvement and was well tolerated and showed significantly improved blood sugar control in patients with type II diabetes.
(NBL) Noble Energy announced new oil and gas discovery in Equatorial Guinea.
(NGI) NEON Communications being acquired for $5.25 per share by RCN Communications.
(NRGN) Neurogen announces positive results for proprietary insomnia drug in two chronic insomnia clinical trials.
(NTDOY) Nintendo passed up Sony in market value in Japan today.
(OMTR) Omniture could be acquired in online ad measuring according to Cramer; stock up 8%.
(OREX) Orexigen Therapeutics announced positive obesity data this weekend American Diabetes Association 67th Scientific Sessions in Chicago.
(USEY) US Energy is seeking third party financial advisors to assist board in its evaluation of potential refinancing or restructuring transactions
(YHOO) Yahoo!’s head executive of US ad sales left for Martha Stewart Ominimedia; Yahoo! is merging ad departments.

Jon C. Ogg
June 25, 2007

JOn Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 25, 2007 – 7:18 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , , , , ,

Biotechs & Pharmas Bracing For ASCO Annual Meeting

This weekend we have the mother of all future cancer treatment conferences: ASCO, or The American Society of Clinical Oncology.  Cancer stocks in the last few weeks have been seeing a muted response ahead of the event that biotech investors have traditionally braced for.  At various points on the website you can find a full list of contributing and presenting companies.  This is only a sample of the companies presenting data and it is very possible that the dates and even the companies may have changed.  Also, you’ll probably start seeing news here at this ASCO News Site either late Thursday evening or Friday. Some of these dates and presentation schedules have been compiled over a multi-week period, so it is very likely that some of these will have changed.

SATURDAY, JUNE 2

Genentech (DNA) will show data with Roche on Avastin plus a chemotherapy dual-mix cocktail for first line treatment in non-small cell lung cancer patients.  Later on at ASCO, a failed Avastin study for the treatment of pancreatic cancer will be shown.  Some Phase III Avastin data in kidney cancer will also be presented next week. Genentech will also be showing data with partners OSI Pharmaceuticals (OSIP) and Imclone (IMCL) in later days.

Pfizer (PFE) will present data on Sutent’s safety and efficacy in Phase II liver cancer studies.

If you forgot about Dendreon (DNDN), this will be the company’s last known data presentation on Provenge after getting the FDA delay.  Investors will be looking closely at any ‘New Data’ presented because much of the ongoing study data is being treated as old data.

Arqule (ARQL) and Exelixis (EXEL) are presenting data as well on molecules that are deemed cancer targets

Others to watch are Onyx Pharmaceuticals (ONXX) and partner Bayer (BAY), because their liver cancer studies are under concern over toxicity.  Its Nexavar data will be presented later for liver cancer Phase III.

Amgen (AMGN) will have study posters up discussing safety of its anemia treatment Aranesp that many patients have to use.  It is no secret that the reimbursement rates, effectiveness and safety, and the dosage have been under fire and worse for some time now.  Most of the damage has been done and many feel that more cautionary and worrisome days are ahead.

Immunogen (IMGN) will be releasing some preliminary data on Herceptin-DM1 in its Genentech pact for the treatment of breast cancer.

Read More »

Posted on: May 30, 2007 – 6:30 pm in Biotech, , , , , , , , , , , , , , , , , , , ,